Navigation Links
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Date:9/4/2007

te enlargement"

This post hoc analysis of the CombAT two-year data is a comparison of efficacy for AVODART and tamsulosin monotherapies. According to the post hoc analysis, AVODART monotherapy resulted in a pattern of continuous and increasing symptom improvement over 2 years (IPSS at Month 3: 2.8 units; IPSS at Month 24: 4.9 units). Patients taking tamsulosin showed similar symptom improvement at Month 3 through Month 24 (IPSS at Month 3: 4.5 units; IPSS at Month 24: 4.3 units). Furthermore, AVODART resulted in continuous and sustained Qmax (urine flow rate) improvements to Month 24.

The third analysis presented covered the safety and tolerability of the treatment regimens. All therapy regimens employed in the study appear to be generally well-tolerated. The profile of events for combination therapy was consistent with those reported for monotherapies. The most common adverse events for combination therapy were erectile dysfunction (7.4%), retrograde ejaculation (4.2%) and altered or decreased libido (3.4%). The most common adverse events for AVODART monotherapy were erectile dysfunction (6.0%), altered or decreased libido (2.8%) and breast enlargement (1.8%), while the most common adverse events for tamsulosin monotherapy were erectile dysfunction (3.8%), altered or decreased libido (1.7%) and dizziness (1.7%).

About CombAT

CombAT is a multicenter, randomized, double-blind and parallel-group study. Men [aged greater than or equal to 50 years with a prostate volume (PV) greater than or equal to 30 cc, serum prostate-specific antigen (PSA) level 1.5-10 ng/mL, Qmax > 5 and less than or equal to 15 mL/sec with a minimum voided volume greater than or equal to 125 mL and International Prostate Symptom Score (IPSS) greater than or equal to 12] with moderate-to-severe enlarged prostate symptoms received placebo for four weeks and were then randomized to receive AVODART 0.5 mg/day and tamsulosin 0.4 mg/day (n=1492), AVODART 0.5 mg/day (n=1502), or t
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien und CALGARY, Alberta , ... Vorgestellt in der "State of the Art and ...    Resverlogix Corp. (TSX: RVX) gab heute ... Affairs bei Resverlogix, beim Kongress des europäischen Kardiologenverbandes (ESC) ... Vortrag gehalten hat. In seinem Vortrag mit dem Titel ...
(Date:9/2/2014)... September 2, 2014 According ... Market Research "Latin America Home Healthcare Market (By ... Healthcare Devices, Mobility Assist Devices and Medical Supplies; ... Infusion Therapy and Unskilled Home Healthcare Services) - ... 2014 - 2020" the Latin American Home Healthcare ...
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
Breaking Medicine Technology:RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10
... /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: WWIN ... medical dressings, medical disposables and non-woven fabric made from 100% ... team will present at the 2011 Brean Murray, Carret & ... 27 and 28, 2011 at the JW Marriott Hotel located ...
... Ingelheim announced today that they will launch a three-year ... world.  The "Making More Health" initiative will promote healthy ... most promising solutions to challenging health problems. ... programs aimed at identifying innovative health solutions, including the ...
Cached Medicine Technology:Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 2Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 3Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health" 2Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health" 3
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
(Date:9/2/2014)... The Dream2Walk Foundation along with Gas Monkey ... 2014 during Spinal Cord Injury Awareness Month featuring full band ... Chuck Ligon. Linear Automotive will be there hosting a Hot ... open at 2pm. The car show is Pre 1964 only, ... to the concert. There will be trophies for top 3 ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Melatonin supplements did ... hip fractures, a new study found. Many older ... delirium due to disruption of their normal sleep-wake cycle. ... factor that contributes to delirium, but there has been ... patients. This study included 378 patients, average age ...
(Date:9/2/2014)... (Sept. 2, 2014) Measuring the levels of sex hormones ... sudden cardiac arrest, a heart rhythm disorder that is fatal ... published online by the peer-reviewed journal Heart Rhythm , ... hormone, were found in men who had a sudden cardiac ... were strongly associated with greater chances of having a sudden ...
(Date:9/2/2014)... When weather conditions are right, tornadoes can occur anywhere ... path of destruction. In fact, the United States leads the ... per year. Rainbow International offers the following safety tips on ... , Select a safe place such as a ... no windows to stay during the storm. If a tornado ...
Breaking Medicine News(10 mins):Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Study links sex hormone levels in the blood to risk of sudden cardiac arrest 2Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2
... prescription drugs, study says , , MONDAY, March 24 (HealthDay ... their doctors end up having significantly higher out-of-pocket costs ... free samples, a new study finds. , In ... in out-of-pocket costs on prescription drugs in the six ...
... March 24 /Xinhua-PRNewswire-FirstCall/ -- China,Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number of,directly ... has,declared a cash dividend on its ordinary share of ... full year 2007. The cash dividend is payable on,or ...
... 24 "Going head-to-head with your child,can be more stacked ... extra reading at bedtime and, before you know it, she,ll ... can,t refuse.,Well, if I can,t stay up late to have ... you owe me a back rub and two books before ...
... HeartWare Inc. (ASX: HTW),a developer and manufacturer ... failure, today announced it has selected Allen & ... corporate communications.,Allen & Caron Inc has offices in ... Chief Executive Douglas Godshall said: "There is a ...
... vitro model (cell culture) research currently underway at the Peninsula ... to identify and develop therapies for the treatment of multiple ... mutations affecting a protein called merlin, which in turn cause ... in the brain. Schwann cells produce the sheaths that surround ...
... From ... its Biodefense and Pandemic Fund, SAN DIEGO, March 24 ... million Series B financing to advance the,clinical development of its ... financing was led by Kleiner,Perkins, Caufield and Byers (KPCB). New ...
Cached Medicine News:Health News:Free Drug Samples Hike Out-of-Pocket Costs 2Health News:Free Drug Samples Hike Out-of-Pocket Costs 3Health News:China Nepstar Chain Drugstore Announces Dividend 2Health News:China Nepstar Chain Drugstore Announces Dividend 3Health News:HOW TO UNSPOIL YOUR CHILD FAST: Harvard Medical School Psychologist Writes Book to Guide and Motivate Parents and Support the Children's Defense Fund 2Health News:HeartWare Selects Allen & Caron for Investor Relations and Corporate Communications 2Health News:Research to lead to brain tumor therapies 2Health News:Research to lead to brain tumor therapies 3Health News:Trius Raises $30 Million in Series B Financing 2
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
... FDA approved, Avagard antiseptic hand prep ... hand scrub brushes and antimicrobial soaps. ... hands for surgery, it's fast-acting and ... for up to six hours without ...
... antimicrobial skin cleanser will not leave your ... frequent washings. With persistent Antimicrobial action, CHG ... microorganisms, including gram-negative and gram-positive bacteria, fungi, ... a 15 second hand wash. The solution ...
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Medicine Products: